Treatment approaches for FGFR-altered urothelial carcinoma: targeted therapies and immunotherapy
The treatment of metastatic urothelial carcinoma has dramatically changed over the past decade with the approval of several therapies from multiple drug classes including immune checkpoint inhibitors, targeted therapies, and antibody drug conjugates. Although next generation sequencing of urothelial...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-08-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1258388/full |
| _version_ | 1797739399707885568 |
|---|---|
| author | David J. Benjamin Robert Hsu |
| author_facet | David J. Benjamin Robert Hsu |
| author_sort | David J. Benjamin |
| collection | DOAJ |
| description | The treatment of metastatic urothelial carcinoma has dramatically changed over the past decade with the approval of several therapies from multiple drug classes including immune checkpoint inhibitors, targeted therapies, and antibody drug conjugates. Although next generation sequencing of urothelial carcinoma has revealed multiple recurring mutations, only one targeted therapy has been developed and approved to date. Erdafitinib, a pan-fibroblast growth factor receptor (FGFR) inhibitor, has been approved for treating patients with select FGFR2 and FGFR3 alterations and fusions since 2019. Since then, emerging data has demonstrated efficacy of combining erdafitinib with immunotherapy in treating FGFR-altered urothelial carcinoma. Ongoing trials are evaluating the use of erdafitinib in non-muscle invasive urothelial carcinoma as well as in combination with enfortumab vedotin in the metastatic setting, while other FGFR targeted agents such as infigratinib, AZD4547, rogaratinib and pemigatinib continue to be in development. Future challenges will include strategies to overcome FGFR acquired resistance and efficacy and safety of combination therapies with erdafitinib and other FGFR targeted agents. |
| first_indexed | 2024-03-12T13:57:39Z |
| format | Article |
| id | doaj.art-4bd3ab3f5d544039bc1eb26388b2b977 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-12T13:57:39Z |
| publishDate | 2023-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-4bd3ab3f5d544039bc1eb26388b2b9772023-08-22T11:30:23ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-08-011410.3389/fimmu.2023.12583881258388Treatment approaches for FGFR-altered urothelial carcinoma: targeted therapies and immunotherapyDavid J. Benjamin0Robert Hsu1Hoag Family Cancer Institute, Newport Beach, CA, United StatesDepartment of Internal Medicine, Division of Medical Oncology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, United StatesThe treatment of metastatic urothelial carcinoma has dramatically changed over the past decade with the approval of several therapies from multiple drug classes including immune checkpoint inhibitors, targeted therapies, and antibody drug conjugates. Although next generation sequencing of urothelial carcinoma has revealed multiple recurring mutations, only one targeted therapy has been developed and approved to date. Erdafitinib, a pan-fibroblast growth factor receptor (FGFR) inhibitor, has been approved for treating patients with select FGFR2 and FGFR3 alterations and fusions since 2019. Since then, emerging data has demonstrated efficacy of combining erdafitinib with immunotherapy in treating FGFR-altered urothelial carcinoma. Ongoing trials are evaluating the use of erdafitinib in non-muscle invasive urothelial carcinoma as well as in combination with enfortumab vedotin in the metastatic setting, while other FGFR targeted agents such as infigratinib, AZD4547, rogaratinib and pemigatinib continue to be in development. Future challenges will include strategies to overcome FGFR acquired resistance and efficacy and safety of combination therapies with erdafitinib and other FGFR targeted agents.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1258388/fullFGFRurothelial carcinomatargeted therapyerdafitinibacquired resistance |
| spellingShingle | David J. Benjamin Robert Hsu Treatment approaches for FGFR-altered urothelial carcinoma: targeted therapies and immunotherapy Frontiers in Immunology FGFR urothelial carcinoma targeted therapy erdafitinib acquired resistance |
| title | Treatment approaches for FGFR-altered urothelial carcinoma: targeted therapies and immunotherapy |
| title_full | Treatment approaches for FGFR-altered urothelial carcinoma: targeted therapies and immunotherapy |
| title_fullStr | Treatment approaches for FGFR-altered urothelial carcinoma: targeted therapies and immunotherapy |
| title_full_unstemmed | Treatment approaches for FGFR-altered urothelial carcinoma: targeted therapies and immunotherapy |
| title_short | Treatment approaches for FGFR-altered urothelial carcinoma: targeted therapies and immunotherapy |
| title_sort | treatment approaches for fgfr altered urothelial carcinoma targeted therapies and immunotherapy |
| topic | FGFR urothelial carcinoma targeted therapy erdafitinib acquired resistance |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1258388/full |
| work_keys_str_mv | AT davidjbenjamin treatmentapproachesforfgfralteredurothelialcarcinomatargetedtherapiesandimmunotherapy AT roberthsu treatmentapproachesforfgfralteredurothelialcarcinomatargetedtherapiesandimmunotherapy |